[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Xiaobo Yang, MD\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100482704","phase-2-the-effects-of-ecmo-on-the-pharmacokinetics-of-hydromorphone-100482704",false,"NCT05565495","The Effects of ECMO on the Pharmacokinetics of Hydromorphone","Inclusion Criteria:\n\n* Between the ages of 18 and 80;\n* Using hydromorphone for pain relief;\n* Using ECMO for more than 96h\n\nExclusion Criteria:\n\n* Allergic to hydromorphone;\n* Use of CRRT during ECMO;\n* Liver function Child-Pugh B, C grade;\n* Pregnancy;\n* Intestinal obstruction;\n* Refused to sign the informed consent.","ALL","18 Years","80 Years",{"count":19,"type":20},26,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study was to establish a population pharmacokinetic (PPK) model of hydromorphone in patients under ECMO, and to recommend a dosing regimen when the target effective concentration was reached.",[26],"Extracorporeal Membrane Oxygenation",[26,28,29],"Pharmacokinetics","Hydromorphone","RECRUITING","2024-08-05",{"date":33,"type":34},"2024-08-06","ACTUAL",{"date":36,"type":34},"2022-01-01",{"date":38,"type":20},"2024-09-01",{"name":40,"class":41},"Xiaobo Yang, MD","OTHER",""]